ABT-702

Last updated

ABT-702
ABT-702.svg
Identifiers
  • 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
Formula C22H19BrN6O
Molar mass 463.339 g·mol−1
3D model (JSmol)
  • C1COCCN1C2=NC=C(C=C2)C3=NC4=NC=NC(=C4C(=C3)C5=CC(=CC=C5)Br)N
  • InChI=1S/C22H19BrN6O/c23-16-3-1-2-14(10-16)17-11-18(28-22-20(17)21(24)26-13-27-22)15-4-5-19(25-12-15)29-6-8-30-9-7-29/h1-5,10-13H,6-9H2,(H2,24,26,27,28)
  • Key:RQCXKDWOCUJWQZ-UHFFFAOYSA-N

ABT-702 is an experimental drug that acts as a selective inhibitor of the enzyme adenosine kinase. In animal studies it has analgesic and antiinflammatory effects, and has been useful in investigating the potential applications of adenosine kinase inhibitors in a number of medical applications. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]

References

  1. ↑ Lee CH, Jiang M, Cowart M, Gfesser G, Perner R, Kim KH, et al. (June 2001). "Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor". Journal of Medicinal Chemistry. 44 (13): 2133–2138. doi:10.1021/jm000314x. PMID   11405650.
  2. ↑ Jarvis MF, Yu H, Kohlhaas K, Alexander K, Lee CH, Jiang M, et al. (December 2000). "ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse". The Journal of Pharmacology and Experimental Therapeutics. 295 (3): 1156–1164. doi:10.1016/S0022-3565(24)39018-4. PMID   11082453.
  3. ↑ Kowaluk EA, Mikusa J, Wismer CT, Zhu CZ, Schweitzer E, Lynch JJ, et al. (December 2000). "ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat". The Journal of Pharmacology and Experimental Therapeutics. 295 (3): 1165–1174. doi:10.1016/S0022-3565(24)39019-6. PMID   11082454.
  4. ↑ Vlajkovic SM, Guo CX, Telang R, Wong AC, Paramananthasivam V, Boison D, et al. (November 2011). "Adenosine kinase inhibition in the cochlea delays the onset of age-related hearing loss". Experimental Gerontology. 46 (11): 905–914. doi:10.1016/j.exger.2011.08.001. PMC   3200489 . PMID   21846498.
  5. ↑ Elsherbiny NM, Ahmad S, Naime M, Elsherbini AM, Fulzele S, Al-Gayyar MM, et al. (July 2013). "ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy". Life Sciences. 93 (2–3): 78–88. doi:10.1016/j.lfs.2013.05.024. PMID   23770229.
  6. ↑ Ahmad S, Elsherbiny NM, Bhatia K, Elsherbini AM, Fulzele S, Liou GI (December 2014). "Inhibition of adenosine kinase attenuates inflammation and neurotoxicity in traumatic optic neuropathy". Journal of Neuroimmunology. 277 (1–2): 96–104. doi:10.1016/j.jneuroim.2014.10.006. PMID   25457840.
  7. ↑ Otsuguro K, Tomonari Y, Otsuka S, Yamaguchi S, Kon Y, Ito S (October 2015). "An adenosine kinase inhibitor, ABT-702, inhibits spinal nociceptive transmission by adenosine release via equilibrative nucleoside transporters in rat". Neuropharmacology. 97: 160–170. doi:10.1016/j.neuropharm.2015.05.035. hdl: 2115/62927 . PMID   26066576.
  8. ↑ Cao W, Yuan Y, Liu X, Li Q, An X, Huang Z, et al. (July 2019). "Adenosine kinase inhibition protects against cisplatin-induced nephrotoxicity". American Journal of Physiology. Renal Physiology. 317 (1): F107 –F115. doi:10.1152/ajprenal.00385.2018. PMID   30995110.
  9. ↑ Wang W, Wang B, Sun S, Cao S, Zhai X, Zhang C, et al. (March 2021). "Inhibition of adenosine kinase attenuates myocardial ischaemia/reperfusion injury". Journal of Cellular and Molecular Medicine. 25 (6): 2931–2943. doi:10.1111/jcmm.16328. PMC   7957171 . PMID   33523568.
  10. ↑ Wölkart G, Gissing S, Stessel H, Fassett EK, Klösch B, Greene RW, et al. (December 2024). "An adenosinergic positive feedback loop extends pharmacological cardioprotection duration". British Journal of Pharmacology. 181 (23): 4920–4936. doi: 10.1111/bph.17331 . PMID   39256947.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.